Immunitas Therapeutics has entered into a global licensing agreement with Boehringer Ingelheim for our preclinical antibody program targeting chronic inflammatory and autoimmune diseases. Based on the data generated by Immunitas to date, this program represents a differentiated approach to treating these conditions. Rather than blocking individual inflammatory signals, our antibody is designed to selectively target the pathogenic cells driving chronic inflammation at the source. The goal: deeper, more durable disease control for patients who haven't found adequate relief with current therapies. Partnering with Boehringer Ingelheim, a global leader with deep immunology expertise, brings us closer to delivering new solutions to patients who need them most. Read the full announcement on our website: https://lnkd.in/dP8M7g5s
Immunitas Therapeutics
Biotechnology Research
Waltham, Massachusetts 9,051 followers
Immunology for Patient Impact
About us
Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Our second program is a novel therapeutic for the treatment of autoimmune disease that builds on our specialized foundational knowledge of the CD161-CLEC2D pathway.
- Website
-
https://www.immunitastx.com/
External link for Immunitas Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Privately Held
- Founded
- 2019
Locations
-
Primary
Get directions
21 Hickory Dr
Waltham, Massachusetts 02451, US
Employees at Immunitas Therapeutics
Updates
-
Greetings from San Diego! At this year’s American Association for Cancer Research Annual Meeting, we’ll share Phase 1/2a data supporting the potential of IMT-009, our first-in-class anti-CD161 antibody, as a novel immunotherapy for difficult-to-treat cancers. Our early clinical results show: - Early anti-tumor activity in heavily pretreated patients with MSS colorectal cancer — including confirmed partial responses both as monotherapy and in combination with fruquintinib - Favorable tolerability in both settings - Emerging biomarker data that may help identify which patients are most likely to benefit from treatment with IMT-009 Visit our poster and read our latest press release to learn more about our presentation: https://lnkd.in/gQt273mZ
-
-
We’ll be on the ground in San Diego for the American Association for Cancer Research 2026 Annual Meeting in April! Stop by our poster to learn more about our first-in-class anti-CD161 antibody, IMT-009, as we present clinical data supporting its potential as a novel cancer immunotherapy. Click here for more information about our presentation: https://bit.ly/4shcAvB #AACR2026 #Immunotherapy #Oncology #Biotech
-
-
This Thursday, November 13, Immunitas CEO Amanda Wagner will participate in a panel with other biotech CEOs and academic founders to discuss the challenges of getting from discovery to the clinic in oncology. All proceeds from this event will benefit Damon Runyon Cancer Research Foundation. Tickets available here: https://lnkd.in/e52uSDyu.
These are tough times for early stage science. Especially in oncology, and especially for first-in-class approaches. Yet this is exactly where the next breakthroughs happen. On November 13 in Cambridge, I’m hosting an evening in support of the Damon Runyon Cancer Research Foundation, featuring two incredible panels - biotech CEOs and academic founders - talking candidly about what it takes to get from discovery to the clinic in an environment that often feels impossible. All proceeds support Damon Runyon’s early-career cancer researchers and my personal goal to raise $50K through the Timmerman Traverse Kilimanjaro Trek this February toward the team's total goal of $1M for cancer research. If you care about bold science and the people who make it happen, I hope you’ll join us. Tickets ($75 donation): https://lnkd.in/e52uSDyu Krista Goodman Amanda Wagner Kate Yen Rachel W. Humphrey, MD Kai Wucherpfennig Vijay Kuchroo
-
-
Our Head of Discovery and Pharmacology, Shruti Malu, Ph.D, will present a poster and give a brief talk on preclinical data for IMT-380 (an anti-CD161 antibody) at the Federation of American Societies for Experimental Biology (FASEB) Science Research Conference on Autoimmunity. We’re excited to present this data in support of expanding our scope from oncology to also include autoimmune conditions. For more information, view the press release here: https://lnkd.in/eRjTG7gc.
-